This company listing is no longer active
76X0 Stock Overview
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Standard BioTools Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.93 |
| 52 Week High | US$3.28 |
| 52 Week Low | US$1.59 |
| Beta | 1.64 |
| 1 Month Change | -14.60% |
| 3 Month Change | 12.21% |
| 1 Year Change | -29.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 76X0 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -13.1% | -2.1% | -1.3% |
| 1Y | -29.6% | -5.8% | 14.9% |
Return vs Industry: 76X0 underperformed the German Life Sciences industry which returned -17.8% over the past year.
Return vs Market: 76X0 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 76X0 volatility | |
|---|---|
| 76X0 Average Weekly Movement | 12.0% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 76X0's share price has been volatile over the past 3 months.
Volatility Over Time: 76X0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 451 | Adam Taich | www.somalogic.com |
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development.
Standard BioTools Inc. Fundamentals Summary
| 76X0 fundamental statistics | |
|---|---|
| Market cap | €361.71m |
| Earnings (TTM) | -€119.03m |
| Revenue (TTM) | €74.61m |
4.8x
P/S Ratio-3.0x
P/E RatioIs 76X0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 76X0 income statement (TTM) | |
|---|---|
| Revenue | US$81.72m |
| Cost of Revenue | US$97.89m |
| Gross Profit | -US$16.16m |
| Other Expenses | US$114.22m |
| Earnings | -US$130.38m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | -19.78% |
| Net Profit Margin | -159.54% |
| Debt/Equity Ratio | 0% |
How did 76X0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/09 13:28 |
| End of Day Share Price | 2024/01/05 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Standard BioTools Inc. is covered by 3 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Brandon Couillard | Jefferies LLC |
| Daniel Brennan | TD Cowen |